<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735680</url>
  </required_header>
  <id_info>
    <org_study_id>ON-1002</org_study_id>
    <nct_id>NCT03735680</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer</brief_title>
  <official_title>A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety, and Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoNano Medicine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoNano Medicine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of
      ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients
      with solid tumors undergoing routine surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure mean fluorescence intensity of histologically confirmed tumor vs normal tissue in patients undergoing routine surgery [Tumor to Background Ratio (TBR)]</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of all treatment-emergent adverse events (TEAEs) from time of ONM-100 administration through Day 28</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetic parameters: Cmax</measure>
    <time_frame>6 days</time_frame>
    <description>Maximum plasma concentration [Cmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetic parameters: Tmax</measure>
    <time_frame>6 days</time_frame>
    <description>Time to Cmax [Tmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetic parameters: AUC</measure>
    <time_frame>6 days</time_frame>
    <description>Area under the time-concentration curve [AUC]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetic parameters: CL</measure>
    <time_frame>6 days</time_frame>
    <description>Total body clearance [CL]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetic parameters: Vss</measure>
    <time_frame>6 days</time_frame>
    <description>Volume of distribution [Vss]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetic parameters: t1/2</measure>
    <time_frame>6 days</time_frame>
    <description>Terminal elimination half-life [t1/2]</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Patients receiving ONM-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in this arm will receive ONM-100 for injection and undergo intraoperative imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONM-100</intervention_name>
    <description>A polymer micelle covalently conjugated to indocyanine green, an FDA-approved fluorophore</description>
    <arm_group_label>Patients receiving ONM-100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-confirmed diagnosis of primary or recurrent respective tumor type and scheduled
             to undergo surgical resection

          -  Part 1: Biopsy-confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC) or
             breast cancer

          -  Part 2: Biopsy-confirmed diagnosis of HNSCC, breast cancer, colorectal cancer,
             prostate cancer, ovarian cancer, urothelial carcinoma and non-small cell lung cancer.

        Exclusion Criteria:

          -  Histologically diagnosed by an excisional biopsy procedure

          -  Tumors at sites of which the surgeon would assess that in vivo intraoperative imaging
             would not be feasible

          -  Life expectancy &lt;12 weeks

          -  Hepatic impairment (Child-Pugh score â‰¥5) or significant liver disease including active
             hepatitis or cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yalia Jayalakshmi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>OncoNano Medicine, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yalia Jayalakshmi, PhD</last_name>
    <phone>650-861-0608</phone>
    <email>jaya@onconanomed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Brooks, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert Zeh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas - M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Hunt, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

